Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Petrova, N.N.
and
Mukhin, A.A.
2022.
Mechanisms of action and clinical effects of vortioxetine.
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova,
Vol. 122,
Issue. 6,
p.
84.
Yuan, Jing
Wu, Changjiang
Wu, Li
Fan, Xinxin
Zeng, Tingting
Xu, Li
Wei, Yujun
Zhang, Yan
Wang, Hongxuan
Peng, Ying
Kang, Chuanyuan
and
Yang, Jianzhong
2022.
The Association of P300 Components With Clinical Characteristics and Efficacy of Pharmacotherapy in Alcohol Use Disorder.
Frontiers in Psychiatry,
Vol. 13,
Issue. ,
De Diego-Adeliño, Javier
Crespo, José Manuel
Mora, Fernando
Neyra, Adrián
Iborra, Pedro
Gutiérrez-Rojas, Luis
and
Salonia, Selman F.
2022.
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review.
Expert Opinion on Drug Safety,
Vol. 21,
Issue. 5,
p.
673.
Barbosa-Méndez, Susana
Perez-Sánchez, Gilberto
and
Salazar-Juárez, Alberto
2022.
Vortioxetine treatment decreases cocaine-induced locomotor sensitization in rats.
Physiology & Behavior,
Vol. 257,
Issue. ,
p.
113989.
Di Nicola, Marco
Pepe, Maria
Panaccione, Isabella
Moccia, Lorenzo
Janiri, Luigi
and
Sani, Gabriele
2023.
Update on Pharmacological Treatment for Comorbid Major Depressive
and Alcohol Use Disorders: The Role of Extended-release Trazodone.
Current Neuropharmacology,
Vol. 21,
Issue. 11,
p.
2195.
Li, Zejun
Liu, Shouhuan
Wu, Qiuxia
Li, Jing
Yang, Qian
Wang, Xin
Peng, Pu
Wang, Qianjin
Liu, Yueheng
Li, Manyun
Hao, Yuzhu
Xu, Huixue
He, Li
Wang, Yunfei
Chen, Shubao
and
Liu, Tieqiao
2023.
Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
International Journal of Neuropsychopharmacology,
Vol. 26,
Issue. 6,
p.
373.
Chen, Ying-Ying
Gui, Zhu
Hu, Di
Chen, Meng-Yuan
He, Jin-Gang
Yu, Si-Yu
Feng, Yu-Qi
Wang, Jie
and
Yuan, Bi-Feng
2024.
Adolescent alcohol exposure changes RNA modifications in adult brain by mass spectrometry-based comprehensive profiling analysis.
Chinese Chemical Letters,
Vol. 35,
Issue. 1,
p.
108522.
Wong, Sabrina
Le, Gia Han
Phan, Lee
Rhee, Taeho Greg
Ho, Roger
Meshkat, Shakila
Teopiz, Kayla M.
Kwan, Angela T.H.
Mansur, Rodrigo B.
Rosenblat, Joshua D.
and
McIntyre, Roger S.
2024.
Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis.
Journal of Affective Disorders,
Vol. 356,
Issue. ,
p.
684.
Di Nicola, M
Adair, M
Rieckmann, A
and
Christensen M, Cronquist
2024.
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.
Journal of Psychopharmacology,
Vol. 38,
Issue. 7,
p.
615.
Cuomo, Alessandro
Aguglia, Andrea
De Berardis, Domenico
Ventriglio, Antonio
Gesi, Camilla
and
Fagiolini, Andrea
2024.
Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine.
Annals of General Psychiatry,
Vol. 23,
Issue. 1,
Wu, Jianhong
Li, Na
Gu, Jun
Shen, Yuan
Qiu, Linghe
and
Zhu, Ling
2025.
Post-marketing safety evaluation of Vortioxetine: A decade-long pharmacovigilance study based on the FAERS database.
Journal of Affective Disorders,
Vol. 379,
Issue. ,
p.
586.
Chiappini, Stefania
Sampogna, Gaia
Ventriglio, Antonio
Menculini, Giulia
Ricci, Valerio
Pettorruso, Mauro
Volpe, Umberto
and
Martinotti, Giovanni
2025.
Emerging strategies and clinical recommendations for the management of novel depression subtypes.
Expert Review of Neurotherapeutics,
Vol. 25,
Issue. 4,
p.
443.
De Filippis, Sergio
Martinotti, Giovanni
Nicoletti, Ferdinando
Mastrostefano, Andrea
Trovini, Giada
Pugliese, Anna
and
Di Nicola, Marco
2025.
Major Depression in Comorbidity with Substance use Disorders: Patients’ Features and Clinical-Neurobiological Rationale of Antidepressant Treatments.
Current Neuropharmacology,
Vol. 23,
Issue. 3,
p.
256.